We are live on ! Find out more
AC

Armistice Capital Portfolio holdings

AUM $5.62B
1-Year Est. Return 36.06%
This Fund
S&P 500
This Quarter Est. Return
-11.81%
1 Year Est. Return
+36.06%
3 Year Est. Return
+44.14%
5 Year Est. Return
+38.37%
10 Year Est. Return
+188.88%
AUM
$5.73M
AUM Growth
-$5.17B
Cap. Flow
-$776M
Cap. Flow %
-13,535.32%
Top 10 Hldgs %
49.82%
Holding
217
New
75
Increased
44
Reduced
24
Closed
41

Top Buys

Rank Stock Value
1
ORLY icon
O'Reilly Automotive
ORLY
+$93.9M
2
LULU icon
lululemon athletica
LULU
+$73.2M
3
DG icon
Dollar General
DG
+$71.9M
4
REGN icon
Regeneron Pharmaceuticals
REGN
+$67.6M
5
NBIX icon
Neurocrine Biosciences
NBIX
+$62.2M

Top Sells

Rank Stock Value
1
HD icon
Home Depot
HD
+$105M
2
BIIB icon
Biogen
BIIB
+$68.7M
3
TGT icon
Target
TGT
+$68.3M
4
BHVN
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
+$62.1M
5
OCDX
Ortho Clinical Diagnostics Holdings plc Ordinary Shares
OCDX
+$62M

Sector Composition

Rank Sector Weight
1 Healthcare 44.4%
2 Consumer Staples 8.91%
3 Consumer Discretionary 7.35%
4 Technology 4.07%
5 Communication Services 1.24%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SPY icon
1
State Street SPDR S&P 500 ETF Trust
SPY
$782B
$1.26M 22.05%
+33,500
New +$13.7M
IWM icon
2
iShares Russell 2000 ETF
IWM
$81.7B
$567K 9.9%
+33,500
New +$6.18M
INCY icon
3
Incyte
INCY
$23.4B
$152K 2.65%
2,000,000
+476,000
+31% +$36.1M
MRTX
4
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$137K 2.4%
2,048,000
+684,000
+50% +$43.5M
SUPN icon
5
Supernus Pharmaceuticals
SUPN
$2.79B
$136K 2.38%
4,712,000
+1,612,000
+52% +$46.2M
PTCT icon
6
PTC Therapeutics
PTCT
$6.52B
$132K 2.3%
3,296,000
+260,000
+9% +$9.12M
NBIX icon
7
Neurocrine Biosciences
NBIX
$17.2B
$129K 2.25%
1,324,000
+674,000
+104% +$62.2M
TVTX icon
8
Travere Therapeutics
TVTX
$5.27B
$129K 2.25%
5,320,000
+362,000
+7% +$9.1M
REGN icon
9
Regeneron Pharmaceuticals
REGN
$70.9B
$111K 1.94%
188,000
+104,000
+124% +$67.6M
ENTA icon
10
Enanta Pharmaceuticals
ENTA
$400M
$97.8K 1.71%
2,070,000
+946,000
+84% +$51.3M
ORLY icon
11
O'Reilly Automotive
ORLY
$71.3B
$92K 1.6%
+2,183,715
New +$93.9M
BMY icon
12
Bristol-Myers Squibb
BMY
$124B
$89K 1.55%
1,156,000
-240,000
-17% -$18.3M
VRTX icon
13
Vertex Pharmaceuticals
VRTX
$123B
$87.9K 1.53%
312,000
+76,000
+32% +$20.3M
ALKS icon
14
Alkermes
ALKS
$8.79B
$87.1K 1.52%
2,924,000
+1,100,000
+60% +$31.6M
MDGL icon
15
Madrigal Pharmaceuticals
MDGL
$12.8B
$78.7K 1.37%
1,100,000
+122,000
+12% +$8.97M
DG icon
16
Dollar General
DG
$27.7B
$75.6K 1.32%
+308,143
New +$71.9M
MDT icon
17
Medtronic
MDT
$106B
$71.8K 1.25%
800,000
+332,000
+71% +$33.6M
CPRX
18
DELISTED
Catalyst Pharmaceutical
CPRX
$71.5K 1.25%
10,200,000
+1,828,000
+22% +$13.4M
ARGX icon
19
argenx
ARGX
$53.8B
$71.2K 1.24%
188,000
-12,000
-6% -$3.87M
DCPH
20
DELISTED
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
$71K 1.24%
5,400,000
-436,000
-7% -$4.81M
CENTA icon
21
Central Garden & Pet Co Class A
CENTA
$2.4B
$65K 1.13%
2,030,000
+110,000
+6% +$3.62M
ILMN icon
22
Illumina
ILMN
$28.2B
$62.5K 1.09%
348,492
+165,508
+90% +$42.3M
LULU icon
23
lululemon athletica
LULU
$13.2B
$62.3K 1.09%
+228,573
New +$73.2M
BUD icon
24
AB InBev
BUD
$156B
$61.3K 1.07%
1,136,000
+158,000
+16% +$8.87M
CRSP icon
25
CRISPR Therapeutics
CRSP
$4.71B
$60.8K 1.06%
1,000,000
-24,000
-2% -$1.41M
1
2 3 4 5

Similar funds

CRC
Curi RMB Capital Chicago, Illinois $5.62B AUM 18.93% 1-Year Est. Return
RMDI
R.M. Davis Inc Portland, Maine $5.63B AUM 21.26% 1-Year Est. Return
F
Folketrygdfondet Oslo Norway, Norway $5.64B AUM 47.16% 1-Year Est. Return
DWM
Diversify Wealth Management Sandy, Utah $5.61B AUM 19.63% 1-Year Est. Return
DCP
DSM Capital Partners Palm Beach Gardens, Florida $5.66B AUM 27.45% 1-Year Est. Return
EW
Evoke Wealth Los Angeles, California $5.57B AUM 23.85% 1-Year Est. Return
AIM
Alphinity Investment Management Sydney, Australia $5.68B AUM 26.72% 1-Year Est. Return
O
Ossiam Paris, France $5.69B AUM 30.95% 1-Year Est. Return

Armistice Capital's Q2 2022 Portfolio in Review

As of Q2 2022, Armistice Capital held 217 positions worth $5.73M, down 100% from $5.17B the previous quarter. Its ten largest holdings account for 50% of the portfolio.

Armistice Capital withdrew a net $776M in Q2 2022, closing 41 positions and reducing 24 holdings. Its most notable exit was Home Depot, an estimated $105M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 44% of assets, down from 45% a quarter earlier, followed by Consumer Staples and Consumer Discretionary.

Against the trend, Armistice Capital opened a new position in O'Reilly Automotive worth $92K.

  • Armistice Capital's largest Q2 2022 buy was O'Reilly Automotive: 2,183,715 shares worth $92K.
  • Armistice Capital added most to Regeneron Pharmaceuticals in Q2 2022, an estimated $67.6M increase.
  • Armistice Capital's biggest Q2 2022 reduction was Biogen, cutting an estimated $68.7M.
  • Armistice Capital fully exited Home Depot in Q2 2022, selling an estimated $105M.
  • Armistice Capital's ten largest holdings make up 50% of its $5.73M portfolio in Q2 2022.
  • Armistice Capital opened 75 new positions and closed 41 in Q2 2022.
  • Armistice Capital's portfolio value fell 100% quarter-over-quarter to $5.73M.

Based on Armistice Capital's 13F filing for Q2 2022, filed 15 Aug 2022.